Virtus Health Ltd is the irst in-vitro fertilization company to became public, reached 7% premium from its offer and sparked hope of renewed life in Australia's IPO market.

It is the biggest exit for a private equity via IPO since the Myer Holdings Ltd fiasco back in 2009.

The strong debut draws hope for fresh investment opportunities and increased willingness to buy private equity backed firms, despite poor performance in the market.

Virtus shares started at A$ 6.01 last Tuesday, just a little above the price set for the float by Quadrant Private Equity, from Sydney. It now closed at A$6.21.

"It is a very good start and the volume is there," expressed by Evan Lucas an IG Strategist based in Melbourne.  Analysts sees potential and a possible start of an upswing in the markets. However, Virtus admitted that due to a key risk of the business it posed a reduction on the rebates patients may claim from the IVF servicing the governments.